FDA OKs Perioperative Immunotherapy for Head and Neck Cancer

(MedPage Today) -- The FDA approved pembrolizumab (Keytruda) for patients with PD-L1-positive resectable locally advanced head and neck squamous cell carcinoma as neoadjuvant monotherapy, continued as adjuvant therapy plus radiotherapy with or...